Whole body MRI: the argument radiologists are having in public
Two national colleges have now opposed screening scans in the well, and the arithmetic explains why.
Key takeaways
- Major radiology colleges have opposed whole body MRI screening in asymptomatic people.
- Incidental findings are common; serious treatable disease is rare.
- Whole body MRI screening has not been shown to reduce mortality in the general asymptomatic population.
- Imaging may be reasonable for people with known cancer predisposition syndromes.
Whole body MRI screening for asymptomatic people has become a visible consumer product, and the specialty that reads the images has been unusually willing to say so publicly. The Canadian Association of Radiologists issued a policy statement in September 2025 opposing whole body MRI as a screening tool in asymptomatic individuals, observing that it is marketed as empowerment but often delivers uncertainty, overdiagnosis and harm. The Royal Australian and New Zealand College of Radiologists reached a similar position in its 2024 statement.
The arithmetic behind those statements is worth spelling out honestly. Scan a healthy adult from head to pelvis and the chance of finding something unexpected is high; published series report incidental findings in a substantial minority to a majority of participants, while the proportion representing a serious treatable disease is small, typically in the low single digits of per cent. Each ambiguous finding then generates a cascade: a repeat scan in six months, a specialist opinion, sometimes a biopsy with its own complication rate, and a period of anxiety that does not fully resolve even when the result is benign. Some detected cancers would never have caused symptoms in that person's lifetime, and there is no way to know at the time which ones.
The other side of the argument deserves a fair hearing. There are people for whom whole body imaging is reasonable and in some protocols standard: those with known cancer predisposition syndromes such as Li-Fraumeni, and certain hereditary tumour conditions where surveillance regimens exist and have been studied in that population. Advocates also point out that population level screening trials are expensive and slow, and that absence of trial evidence in the well is not the same as evidence of no benefit. That is true, and it is not an argument for selling scans in the meantime.
What the evidence does not support is any claim that whole body MRI screening reduces mortality or improves outcomes in the general asymptomatic population. No trial has shown it, and the harms are concrete while the benefit remains hypothetical.
Notes and sources
Each regulatory statement in this article is set against the document it comes from, so you can read the original rather than our summary of it.
1. Professional body position on whole body screening MRI in asymptomatic people
American College of Radiology statement on whole body screening
2. European professional guidance on imaging and incidental findings
3. Screening tests offered directly to consumers are still regulated devices and services
